[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7IZMjdMAk1qSNzHT8_yhh9SB-6ffEQPq_AbJ4-A7I7k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"University of Oslo",[4,6],"University of Oslo School of Pharmacy",193,false,27,7,7823562,0,154,[15,18,21,23,26,28,31,33],{"name":16,"count":17},"Depression",15,{"name":19,"count":20},"Anxiety",11,{"name":22,"count":10},"Healthy",{"name":24,"count":25},"Periodontal Diseases",5,{"name":27,"count":25},"Anxiety Disorders",{"name":29,"count":30},"Furcation Defects",4,{"name":32,"count":30},"Renal Transplantation",{"name":34,"count":35},"Malnutrition",3,[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,101,140,174,204,233,259,277,302,328,346,374,392,420,438,456,481,506,531,556,574,603,621,639,663,688,712,736,761,779,797,822,848,866,890,914,938,963,981,1005,1030,1054,1079,1105,1132],{"intervention":46,"totalTrials":30,"cells":47},"cyclosporine A",{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":99},{"trials":49,"activeCount":12},[],{"trials":51,"activeCount":12},[],{"trials":53,"activeCount":12},[],{"trials":55,"activeCount":12},[],{"trials":57,"activeCount":12},[58,69,80,90],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"start":64,"enrollment":65,"conditions":66,"interventions":68},"NCT00139035","Effects of Cyclosporine A on Pancreatic Insulin Secretion","COMPLETED",[42],"2006-01","2005-04",16,[67],"Chronic Renal Failure",[46],{"nctId":70,"briefTitle":71,"status":61,"phases":72,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":79},"NCT00264355","Metabolic Pattern of Cyclosporine A and Acute Renal Failure",[42],"2007-06","2005-12",30,[77,78],"Heart Transplantation","Acute Renal Failure",[46],{"nctId":81,"briefTitle":82,"status":61,"phases":83,"primaryCompletion":84,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":88},"NCT00525681","Interaction Between Rimonabant and Cyclosporine and Tacrolimus",[42],"2008-05","2007-09",18,[32],[46,89],"tacrolimus",{"nctId":91,"briefTitle":92,"status":61,"phases":93,"completion":94,"start":95,"enrollment":75,"conditions":96,"interventions":97},"NCT00139009","Intracellular and Renal\u002FMyocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation",[42],"2006-09","2005-06",[32,77],[98],"Cyclosporine A",{"trials":100,"activeCount":12},[],{"intervention":102,"totalTrials":35,"cells":103},"Tacrolimus",{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":138},{"trials":105,"activeCount":12},[],{"trials":107,"activeCount":12},[],{"trials":109,"activeCount":12},[],{"trials":111,"activeCount":12},[],{"trials":113,"activeCount":12},[114,124,134],{"nctId":115,"briefTitle":116,"status":61,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"NCT01698541","Generic Tacrolimus in the Elderly - Prograf® vs Tacni®",[42],"2013-11","2013-02",28,[122],"End Stage Renal Disease",[102,102],{"nctId":125,"briefTitle":126,"status":61,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT01092806","Insulin Secretion and Advagraf",[42],"2010-05","2009-10",20,[132],"Post Transplant Diabetes Mellitus",[102],{"nctId":81,"briefTitle":82,"status":61,"phases":135,"primaryCompletion":84,"completion":84,"start":85,"enrollment":86,"conditions":136,"interventions":137},[42],[32],[46,89],{"trials":139,"activeCount":12},[],{"intervention":141,"totalTrials":142,"cells":143},"Atorvastatin",2,{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":172},{"trials":145,"activeCount":12},[],{"trials":147,"activeCount":12},[],{"trials":149,"activeCount":12},[],{"trials":151,"activeCount":12},[],{"trials":153,"activeCount":12},[154,164],{"nctId":155,"briefTitle":156,"status":61,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT00414531","Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity",[42],"2009-06","2005-05",53,[162],"Myotoxicity of Atorvastatin Treatment",[141],{"nctId":165,"briefTitle":166,"status":61,"phases":167,"completion":64,"start":168,"conditions":169,"interventions":171},"NCT00120055","Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity",[42],"2005-02",[170],"Myopathy",[141],{"trials":173,"activeCount":12},[],{"intervention":175,"totalTrials":142,"cells":176},"Biphasic calcium phosphate",{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":202},{"trials":178,"activeCount":12},[],{"trials":180,"activeCount":12},[],{"trials":182,"activeCount":12},[],{"trials":184,"activeCount":12},[],{"trials":186,"activeCount":12},[187,196],{"nctId":188,"briefTitle":189,"status":190,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":25,"conditions":194,"interventions":195},"NCT04059445","Mandibular Furcation II Regeneration","TERMINATED",[42],"2023-11-27","2019-10-15",[29,24],[175],{"nctId":197,"briefTitle":198,"status":190,"phases":199,"primaryCompletion":192,"completion":192,"start":193,"enrollment":25,"conditions":200,"interventions":201},"NCT04059458","Mandibular Furcation III Regeneration (FURC-III-REGEN)",[42],[29,24],[175],{"trials":203,"activeCount":12},[],{"intervention":205,"totalTrials":206,"cells":207},"Metronidazol",1,{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":231},{"trials":209,"activeCount":12},[],{"trials":211,"activeCount":12},[],{"trials":213,"activeCount":12},[],{"trials":215,"activeCount":12},[],{"trials":217,"activeCount":12},[218],{"nctId":219,"briefTitle":220,"status":221,"phases":222,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":230},"NCT01318928","The Treatment of Periodontal Diseases","UNKNOWN",[42],"2010-09","2016-10","2008-01",184,[228,229],"Digestive System Disorders","Adverse Effects",[205],{"trials":232,"activeCount":12},[],{"intervention":234,"totalTrials":206,"cells":235},"Mycophenolate mofetil withdrawal",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":257},{"trials":237,"activeCount":12},[],{"trials":239,"activeCount":12},[],{"trials":241,"activeCount":12},[],{"trials":243,"activeCount":12},[],{"trials":245,"activeCount":12},[246],{"nctId":247,"briefTitle":248,"status":190,"phases":249,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT00148252","Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant",[42],"2005-11","2007-02","2003-02",298,[32],[234,256],"Cyclosporione A withdrawal",{"trials":258,"activeCount":12},[],{"intervention":256,"totalTrials":206,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":275},{"trials":262,"activeCount":12},[],{"trials":264,"activeCount":12},[],{"trials":266,"activeCount":12},[],{"trials":268,"activeCount":12},[],{"trials":270,"activeCount":12},[271],{"nctId":247,"briefTitle":248,"status":190,"phases":272,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":273,"interventions":274},[42],[32],[234,256],{"trials":276,"activeCount":12},[],{"intervention":278,"totalTrials":206,"cells":279},"Nifedipine",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":300},{"trials":281,"activeCount":12},[],{"trials":283,"activeCount":12},[],{"trials":285,"activeCount":12},[],{"trials":287,"activeCount":12},[],{"trials":289,"activeCount":12},[290],{"nctId":291,"briefTitle":292,"status":61,"phases":293,"completion":294,"start":295,"enrollment":130,"conditions":296,"interventions":299},"NCT00244530","Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery",[42],"2005-10","2001-06",[297,298],"Kidney Failure, Chronic","Coronary Artery Disease",[278],{"trials":301,"activeCount":12},[],{"intervention":303,"totalTrials":206,"cells":304},"Ibuprofen",{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":326},{"trials":306,"activeCount":12},[],{"trials":308,"activeCount":12},[],{"trials":310,"activeCount":12},[],{"trials":312,"activeCount":12},[],{"trials":314,"activeCount":12},[315],{"nctId":316,"briefTitle":317,"status":61,"phases":318,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT01849926","Ibuprofen Versus Mecillinam for Uncomplicated Cystitis",[42],"2016-07","2013-04",383,[323],"Acute Cystitis (Excl in Pregnancy)",[303,325],"Mecillinam",{"trials":327,"activeCount":12},[],{"intervention":325,"totalTrials":206,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":344},{"trials":331,"activeCount":12},[],{"trials":333,"activeCount":12},[],{"trials":335,"activeCount":12},[],{"trials":337,"activeCount":12},[],{"trials":339,"activeCount":12},[340],{"nctId":316,"briefTitle":317,"status":61,"phases":341,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":342,"interventions":343},[42],[323],[303,325],{"trials":345,"activeCount":12},[],{"intervention":347,"totalTrials":206,"cells":348},"Chlorhexidine 0.2%, Corsodyl",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":372},{"trials":350,"activeCount":12},[],{"trials":352,"activeCount":12},[],{"trials":354,"activeCount":12},[],{"trials":356,"activeCount":12},[],{"trials":358,"activeCount":12},[359],{"nctId":360,"briefTitle":361,"status":221,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":370},"NCT04223076","Clinical Effect of Chlorhexidine Mouthwash After Periodontal Surgery",[42],"2019-12-20","2020-12-30","2019-03-20",31,[24,368,369],"Periodontitis","Dental Plaque",[347,371],"Chlorhexidine 0.2%, Curasept",{"trials":373,"activeCount":12},[],{"intervention":371,"totalTrials":206,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":390},{"trials":377,"activeCount":12},[],{"trials":379,"activeCount":12},[],{"trials":381,"activeCount":12},[],{"trials":383,"activeCount":12},[],{"trials":385,"activeCount":12},[386],{"nctId":360,"briefTitle":361,"status":221,"phases":387,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":388,"interventions":389},[42],[24,368,369],[347,371],{"trials":391,"activeCount":12},[],{"intervention":393,"totalTrials":206,"cells":394},"triamcinolone",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":418},{"trials":396,"activeCount":12},[],{"trials":398,"activeCount":12},[],{"trials":400,"activeCount":12},[],{"trials":402,"activeCount":12},[],{"trials":404,"activeCount":12},[405],{"nctId":406,"briefTitle":407,"status":61,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":415},"NCT00826462","Treatment Study of Steroid Injection and Physical Therapy for Acute Lateral Epicondylitis",[42],"2013-06","2009-03",177,[413,414],"Tennis Elbow","Epicondylitis, Lateral Humeral",[393,416,417],"Lidocaine","Naproxen",{"trials":419,"activeCount":12},[],{"intervention":416,"totalTrials":206,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":436},{"trials":423,"activeCount":12},[],{"trials":425,"activeCount":12},[],{"trials":427,"activeCount":12},[],{"trials":429,"activeCount":12},[],{"trials":431,"activeCount":12},[432],{"nctId":406,"briefTitle":407,"status":61,"phases":433,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":434,"interventions":435},[42],[413,414],[393,416,417],{"trials":437,"activeCount":12},[],{"intervention":417,"totalTrials":206,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":454},{"trials":441,"activeCount":12},[],{"trials":443,"activeCount":12},[],{"trials":445,"activeCount":12},[],{"trials":447,"activeCount":12},[],{"trials":449,"activeCount":12},[450],{"nctId":406,"briefTitle":407,"status":61,"phases":451,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":452,"interventions":453},[42],[413,414],[393,416,417],{"trials":455,"activeCount":12},[],{"intervention":457,"totalTrials":206,"cells":458},"Experimental: essential oils and ELA",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":479},{"trials":460,"activeCount":12},[],{"trials":462,"activeCount":12},[],{"trials":464,"activeCount":12},[],{"trials":466,"activeCount":12},[],{"trials":468,"activeCount":12},[469],{"nctId":470,"briefTitle":471,"status":61,"phases":472,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},"NCT02884817","Essential Oil+ELA, Plaque and Gingivitis",[42],"2015-10","2015-09",59,[369,477],"Gingivitis",[457],{"trials":480,"activeCount":12},[],{"intervention":482,"totalTrials":206,"cells":483},"Methenamine Hippurate 1000 MG",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":504},{"trials":485,"activeCount":12},[],{"trials":487,"activeCount":12},[],{"trials":489,"activeCount":12},[],{"trials":491,"activeCount":12},[],{"trials":493,"activeCount":12},[494],{"nctId":495,"briefTitle":496,"status":61,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":503},"NCT04077580","The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI",[42],"2023-06-30","2019-11-01",289,[502],"Recurrent Urinary Tract Infection",[482],{"trials":505,"activeCount":12},[],{"intervention":507,"totalTrials":206,"cells":508},"sitagliptin",{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":529},{"trials":510,"activeCount":12},[],{"trials":512,"activeCount":12},[],{"trials":514,"activeCount":12},[],{"trials":516,"activeCount":12},[],{"trials":518,"activeCount":12},[519],{"nctId":520,"briefTitle":521,"status":61,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":528},"NCT00740363","Sitagliptin in Renal Transplant Recipients",[42],"2012-06","2008-09",25,[527],"Glucose Intolerance",[507],{"trials":530,"activeCount":12},[],{"intervention":532,"totalTrials":206,"cells":533},"Zenapax®, CellCept® and prednisolone",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":554},{"trials":535,"activeCount":12},[],{"trials":537,"activeCount":12},[],{"trials":539,"activeCount":12},[],{"trials":541,"activeCount":12},[],{"trials":543,"activeCount":12},[544],{"nctId":545,"briefTitle":546,"status":61,"phases":547,"completion":168,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT00138970","Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk",[42],"2002-01",70,[551],"Renal Transplant Recipients",[532,553],"Sandimmun Neoral®, CellCept® and prednisolone",{"trials":555,"activeCount":12},[],{"intervention":553,"totalTrials":206,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":572},{"trials":559,"activeCount":12},[],{"trials":561,"activeCount":12},[],{"trials":563,"activeCount":12},[],{"trials":565,"activeCount":12},[],{"trials":567,"activeCount":12},[568],{"nctId":545,"briefTitle":546,"status":61,"phases":569,"completion":168,"start":548,"enrollment":549,"conditions":570,"interventions":571},[42],[551],[532,553],{"trials":573,"activeCount":12},[],{"intervention":575,"totalTrials":206,"cells":576},"0.12 % chlorhexidine + 0.2 % NaF mouthrinse",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":601},{"trials":578,"activeCount":12},[],{"trials":580,"activeCount":12},[],{"trials":582,"activeCount":12},[],{"trials":584,"activeCount":12},[],{"trials":586,"activeCount":12},[587],{"nctId":588,"briefTitle":589,"status":61,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":598},"NCT02935322","Interaction Between Chlorhexidine and Fluoride",[42],"2011-12","2012-02","2009-09",32,[596,597],"Periodontal Disease","Dental Caries",[575,599,600],"0.2 % NaF mouthrinse","0.12% chlorhexidine",{"trials":602,"activeCount":12},[],{"intervention":599,"totalTrials":206,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":619},{"trials":606,"activeCount":12},[],{"trials":608,"activeCount":12},[],{"trials":610,"activeCount":12},[],{"trials":612,"activeCount":12},[],{"trials":614,"activeCount":12},[615],{"nctId":588,"briefTitle":589,"status":61,"phases":616,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":617,"interventions":618},[42],[596,597],[575,599,600],{"trials":620,"activeCount":12},[],{"intervention":600,"totalTrials":206,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":631,"NA":637},{"trials":624,"activeCount":12},[],{"trials":626,"activeCount":12},[],{"trials":628,"activeCount":12},[],{"trials":630,"activeCount":12},[],{"trials":632,"activeCount":12},[633],{"nctId":588,"briefTitle":589,"status":61,"phases":634,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":635,"interventions":636},[42],[596,597],[575,599,600],{"trials":638,"activeCount":12},[],{"intervention":640,"totalTrials":206,"cells":641},"Rosuvastatin",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":661},{"trials":643,"activeCount":12},[],{"trials":645,"activeCount":12},[],{"trials":647,"activeCount":12},[],{"trials":649,"activeCount":12},[],{"trials":651,"activeCount":12},[652],{"nctId":653,"briefTitle":654,"status":61,"phases":655,"primaryCompletion":656,"completion":656,"start":592,"enrollment":130,"conditions":657,"interventions":660},"NCT01524601","The Rosuvastatin In TrAnsplant Recipients Study",[42],"2012-10",[658,659],"Disorder Related to Renal Transplantation","Hypercholesterolemia",[640],{"trials":662,"activeCount":12},[],{"intervention":664,"totalTrials":206,"cells":665},"Nateglinide",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":686},{"trials":667,"activeCount":12},[],{"trials":669,"activeCount":12},[],{"trials":671,"activeCount":12},[],{"trials":673,"activeCount":12},[],{"trials":675,"activeCount":12},[676],{"nctId":677,"briefTitle":678,"status":61,"phases":679,"completion":680,"start":681,"enrollment":17,"conditions":682,"interventions":685},"NCT00319189","Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients",[42],"2003-11","2002-11",[551,683,684],"Posttransplant Diabetes Mellitus","Posttransplant Impaired Glucose Tolerance",[664],{"trials":687,"activeCount":12},[],{"intervention":689,"totalTrials":206,"cells":690},"intravenous (IV) ganciclovir",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":697,"PHASE4":699,"NA":710},{"trials":692,"activeCount":12},[],{"trials":694,"activeCount":12},[],{"trials":696,"activeCount":12},[],{"trials":698,"activeCount":12},[],{"trials":700,"activeCount":12},[701],{"nctId":702,"briefTitle":703,"status":190,"phases":704,"completion":73,"start":74,"enrollment":705,"conditions":706,"interventions":709},"NCT00264368","Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy",[42],6,[78,707,708],"Cytomegalovirus Infections","Multi Organ Failure",[689],{"trials":711,"activeCount":12},[],{"intervention":713,"totalTrials":206,"cells":714},"Acetazolamide",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":734},{"trials":716,"activeCount":12},[],{"trials":718,"activeCount":12},[],{"trials":720,"activeCount":12},[],{"trials":722,"activeCount":12},[],{"trials":724,"activeCount":12},[725],{"nctId":726,"briefTitle":727,"status":61,"phases":728,"primaryCompletion":729,"completion":729,"start":548,"enrollment":549,"conditions":730,"interventions":733},"NCT00222534","Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis",[42],"2009-12",[731,732],"Respiratory Insufficiency","Alkalosis",[713],{"trials":735,"activeCount":12},[],{"intervention":737,"totalTrials":206,"cells":738},"Chlorhexidine 0.2% Mouthrinse",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":759},{"trials":740,"activeCount":12},[],{"trials":742,"activeCount":12},[],{"trials":744,"activeCount":12},[],{"trials":746,"activeCount":12},[],{"trials":748,"activeCount":12},[749],{"nctId":750,"briefTitle":751,"status":221,"phases":752,"primaryCompletion":753,"completion":754,"start":753,"enrollment":475,"conditions":755,"interventions":756},"NCT02911766","Efficacy of Different Chlorhexidine Concentrations",[42],"2016-11","2016-12",[369,477],[737,757,758],"Chlorhexidine 0.12% mouthrinse","Chlorhexidine 0.06% mouthrinse",{"trials":760,"activeCount":12},[],{"intervention":757,"totalTrials":206,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":771,"NA":777},{"trials":764,"activeCount":12},[],{"trials":766,"activeCount":12},[],{"trials":768,"activeCount":12},[],{"trials":770,"activeCount":12},[],{"trials":772,"activeCount":12},[773],{"nctId":750,"briefTitle":751,"status":221,"phases":774,"primaryCompletion":753,"completion":754,"start":753,"enrollment":475,"conditions":775,"interventions":776},[42],[369,477],[737,757,758],{"trials":778,"activeCount":12},[],{"intervention":758,"totalTrials":206,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":795},{"trials":782,"activeCount":12},[],{"trials":784,"activeCount":12},[],{"trials":786,"activeCount":12},[],{"trials":788,"activeCount":12},[],{"trials":790,"activeCount":12},[791],{"nctId":750,"briefTitle":751,"status":221,"phases":792,"primaryCompletion":753,"completion":754,"start":753,"enrollment":475,"conditions":793,"interventions":794},[42],[369,477],[737,757,758],{"trials":796,"activeCount":12},[],{"intervention":798,"totalTrials":206,"cells":799},"Go Medical Naltrexone implants",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":818,"NA":820},{"trials":801,"activeCount":12},[],{"trials":803,"activeCount":12},[],{"trials":805,"activeCount":12},[],{"trials":807,"activeCount":12},[808],{"nctId":809,"briefTitle":810,"status":61,"phases":811,"primaryCompletion":812,"completion":813,"start":63,"enrollment":814,"conditions":815,"interventions":817},"NCT00521157","Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction",[40,41],"2008-06","2008-12",56,[816],"Opiate Dependence",[798],{"trials":819,"activeCount":12},[],{"trials":821,"activeCount":12},[],{"intervention":823,"totalTrials":206,"cells":824},"Naltrexone intramuscular suspension",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":844,"NA":846},{"trials":826,"activeCount":12},[],{"trials":828,"activeCount":12},[],{"trials":830,"activeCount":12},[],{"trials":832,"activeCount":12},[833],{"nctId":834,"briefTitle":835,"status":61,"phases":836,"primaryCompletion":837,"completion":838,"start":656,"enrollment":839,"conditions":840,"interventions":842},"NCT01717963","Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway",[41],"2016-08-31","2018-04-30",166,[841],"Opioid Dependence",[823,843],"Buprenorphine-naloxone",{"trials":845,"activeCount":12},[],{"trials":847,"activeCount":12},[],{"intervention":843,"totalTrials":206,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":862,"NA":864},{"trials":851,"activeCount":12},[],{"trials":853,"activeCount":12},[],{"trials":855,"activeCount":12},[],{"trials":857,"activeCount":12},[858],{"nctId":834,"briefTitle":835,"status":61,"phases":859,"primaryCompletion":837,"completion":838,"start":656,"enrollment":839,"conditions":860,"interventions":861},[41],[841],[823,843],{"trials":863,"activeCount":12},[],{"trials":865,"activeCount":12},[],{"intervention":867,"totalTrials":206,"cells":868},"Implantation of naltrexone implants",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":886,"NA":888},{"trials":870,"activeCount":12},[],{"trials":872,"activeCount":12},[],{"trials":874,"activeCount":12},[],{"trials":876,"activeCount":12},[877],{"nctId":878,"briefTitle":879,"status":190,"phases":880,"primaryCompletion":881,"completion":881,"start":159,"enrollment":882,"conditions":883,"interventions":885},"NCT00269607","Naltrexone Implants as Relapse Prevention",[40,41],"2006-12",12,[884],"Opioid Dependency",[867],{"trials":887,"activeCount":12},[],{"trials":889,"activeCount":12},[],{"intervention":891,"totalTrials":206,"cells":892},"Antioxidant-rich food items",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":894,"activeCount":12},[],{"trials":896,"activeCount":12},[],{"trials":898,"activeCount":12},[899],{"nctId":900,"briefTitle":901,"status":61,"phases":902,"completion":903,"start":252,"enrollment":904,"conditions":905,"interventions":907},"NCT00520819","Oslo Antioxidant Study",[39,40],"2005-03",102,[906],"Cardiovascular Disease",[891],{"trials":909,"activeCount":12},[],{"trials":911,"activeCount":12},[],{"trials":913,"activeCount":12},[],{"intervention":915,"totalTrials":206,"cells":916},"Blueberry juice",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":918,"activeCount":12},[],{"trials":920,"activeCount":12},[],{"trials":922,"activeCount":12},[923],{"nctId":924,"briefTitle":925,"status":61,"phases":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":931},"NCT00520871","The Water-Blueberry Study",[39,40],"2004-04","2003-03",62,[906],[915],{"trials":933,"activeCount":12},[],{"trials":935,"activeCount":12},[],{"trials":937,"activeCount":12},[],{"intervention":939,"totalTrials":206,"cells":940},"Naltrexone",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":942,"activeCount":12},[],{"trials":944,"activeCount":12},[],{"trials":946,"activeCount":12},[947],{"nctId":948,"briefTitle":949,"status":61,"phases":950,"primaryCompletion":951,"completion":813,"start":159,"enrollment":952,"conditions":953,"interventions":955},"NCT00204243","Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services",[40],"2008-02",46,[954],"Opiate Addiction",[939,956],"Methadone",{"trials":958,"activeCount":12},[],{"trials":960,"activeCount":12},[],{"trials":962,"activeCount":12},[],{"intervention":956,"totalTrials":206,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":975,"PHASE4":977,"NA":979},{"trials":966,"activeCount":12},[],{"trials":968,"activeCount":12},[],{"trials":970,"activeCount":12},[971],{"nctId":948,"briefTitle":949,"status":61,"phases":972,"primaryCompletion":951,"completion":813,"start":159,"enrollment":952,"conditions":973,"interventions":974},[40],[954],[939,956],{"trials":976,"activeCount":12},[],{"trials":978,"activeCount":12},[],{"trials":980,"activeCount":12},[],{"intervention":982,"totalTrials":206,"cells":983},"Arista AH hemostasis powder",{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":985,"activeCount":12},[],{"trials":987,"activeCount":12},[],{"trials":989,"activeCount":12},[990],{"nctId":991,"briefTitle":992,"status":61,"phases":993,"completion":994,"start":995,"enrollment":75,"conditions":996,"interventions":998},"NCT00227084","Effect of Arista Powder on Bleeding in Reductive Mammary Surgery",[40],"2006-10","2005-09",[997],"Mammaplasty",[982],{"trials":1000,"activeCount":12},[],{"trials":1002,"activeCount":12},[],{"trials":1004,"activeCount":12},[],{"intervention":1006,"totalTrials":206,"cells":1007},"Mesna",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1009,"activeCount":12},[],{"trials":1011,"activeCount":12},[1012],{"nctId":1013,"briefTitle":1014,"status":61,"phases":1015,"primaryCompletion":1016,"completion":1016,"start":1017,"enrollment":525,"conditions":1018,"interventions":1021},"NCT04449536","Cysteine-lowering Treatment With Mesna",[39],"2021-10-21","2020-11-02",[1019,1020],"Obesity","Drug Effect",[1006],{"trials":1023,"activeCount":12},[],{"trials":1025,"activeCount":12},[],{"trials":1027,"activeCount":12},[],{"trials":1029,"activeCount":12},[],{"intervention":1031,"totalTrials":206,"cells":1032},"Melatonin",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1046,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1034,"activeCount":12},[],{"trials":1036,"activeCount":12},[1037],{"nctId":1038,"briefTitle":1039,"status":61,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":882,"conditions":1043,"interventions":1045},"NCT01741389","The Role of Melatonin in the Regulation of Blood Coagulation",[39],"2014-03","2012-12",[1044],"Spinal Cord Injured, Tetraplegia",[1031],{"trials":1047,"activeCount":12},[],{"trials":1049,"activeCount":12},[],{"trials":1051,"activeCount":12},[],{"trials":1053,"activeCount":12},[],{"intervention":1055,"totalTrials":206,"cells":1056},"Control",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1058,"activeCount":12},[],{"trials":1060,"activeCount":12},[],{"trials":1062,"activeCount":12},[],{"trials":1064,"activeCount":12},[],{"trials":1066,"activeCount":12},[],{"trials":1068,"activeCount":12},[1069],{"nctId":1070,"briefTitle":1071,"status":221,"phases":1072,"primaryCompletion":1017,"completion":1073,"start":1074,"enrollment":1075,"conditions":1076,"interventions":1078},"NCT03293342","Cognitive Behavioural Therapy and Dental Fear",[43],"2022-12-20","2017-09-10",96,[1077],"Dental Fear",[1055],{"intervention":1080,"totalTrials":206,"cells":1081},"Systematic drug review",{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1090,"NA":1092},{"trials":1083,"activeCount":12},[],{"trials":1085,"activeCount":12},[],{"trials":1087,"activeCount":12},[],{"trials":1089,"activeCount":12},[],{"trials":1091,"activeCount":12},[],{"trials":1093,"activeCount":12},[1094],{"nctId":1095,"briefTitle":1096,"status":221,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1104},"NCT04228900","Malnutrition in Older Adults: An Intervention Based on Medication Review and Individual Nutritional Plan",[43],"2023-07","2020-08-24",50,[34,1102,1103],"Polypharmacy","Aged",[1080],{"intervention":1106,"totalTrials":206,"cells":1107},"Oxycodone",{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1109,"activeCount":12},[],{"trials":1111,"activeCount":12},[],{"trials":1113,"activeCount":12},[],{"trials":1115,"activeCount":12},[],{"trials":1117,"activeCount":12},[],{"trials":1119,"activeCount":12},[1120],{"nctId":1121,"briefTitle":1122,"status":61,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1131},"NCT06485817","How Stress Alters Opioid Drug Effects",[43],"2022-04-28","2021-11-15",80,[1128,1020,1129,1130],"Motivation","Stress Reaction","Misuse, Opioid",[1106],{"intervention":1133,"totalTrials":206,"cells":1134},"Tetracyclin ointment",{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1136,"activeCount":12},[],{"trials":1138,"activeCount":12},[],{"trials":1140,"activeCount":12},[],{"trials":1142,"activeCount":12},[],{"trials":1144,"activeCount":12},[],{"trials":1146,"activeCount":12},[1147],{"nctId":1148,"briefTitle":1149,"status":61,"phases":1150,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1157},"NCT03494972","A Tetracycline Drain Reduces Alveolar Osteitis in Third Molar Surgery",[43],"2017-03-01","2018-02-01","2016-01-02",200,[1156],"Post-Operative Wound Infection",[1133]]